Amphotericin B Treatment in Visceral Leishmaniasis This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conven...

• Country India
• organs None
• Specialty None

Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when i...

• Country None
• organs None
• Specialty None

Combination Chemotherapy for the Treatment of Indian Kala-Azar The investigators are using a sequential design to combine miltefosine and AmBisome in different doses.

• Country None
• organs None
• Specialty None

Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Miltefosine and liposomal amphotericin B (AmBisome) are approved drugs for visceral leishmaniasis. In this study both drugs will be given in a sequential manner. AmBisome will be given on ...

• Country None
• organs None
• Specialty None

Combination Therapy in Indian Visceral Leishmaniasis Rationale The overall objective of this trial is to identify a safe and effective combination, (co-administration) short course treatment for the treatment of VL which could be easily ...

• Country None
• organs None
• Specialty None

SCH708980 With and Without AmBisome for Visceral Leishmaniasis Background: - Visceral leishmaniasis (VL) is an infection caused by parasites carried by sand flies. The parasites cause fever, weight loss, and enlargement of the spleen and liver. They ...

• Country None
• organs None
• Specialty None